Whether this has implications for stratifying NHL patients for molecular-based prognostication and for targeted therapy has to be investigated in new clinical trials using R-CHOP and/or currently introduced targeted drugs for Btk, PI3K and NF-kB pathways or BET-domain containing protein inhibitors [25, 48, 51, 60]. The gene discussed is NFKB1; the disease is non-Hodgkin lymphoma.